Recombinant human TGF-β protein, a stimulator of the TGF-β pathway, and galunisertib, which is a specific inhibitor of TGF-β receptor (TGF-βR) and has been tested to treat breast cancer in clinical trials (32), or their combination were added to cultured cells. This evidence concerns the gene TGFB1 and breast carcinoma.